NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
%20data%20for%20rosiglitazone%2C%20MRL24%2C%20probe%20ML244%20and%20SR1848.&p=BOOKS&id=143191_ml244f13.jpg "Click on image to zoom")
Figure 13Differential Hydrogen-Deuterium Exchange (HDX) data for rosiglitazone, MRL24, probe ML244 and SR1848
The sequence of each PPAR peptide is given in the left column, along with charge state of the ion (z), and both the PPARγ1 (gamma 1) and PPARγ2 (gamma 2) start/end residue numbers. The %D values indicate the difference between the mean HDX value obtained from apo PPARγ LBD measured at 6 time points (10s, 30s, 60s, 300s, 900s, 3600s) minus the mean value obtained from the “ligand” data collected at the same time point. Each result shows the average of three replicate experiments. The number in parentheses represents the standard deviation of the measurements. Residues S273 (PPARγ 2) and S342 (PPARγ1) are highlighted in red.
- PMCPubMed Central citations
- PubChem BioAssay for Chemical ProbePubChem BioAssay records reporting screening data for the development of the chemical probe(s) described in this book chapter
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.[Nature. 2011]Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB, et al. Nature. 2011 Sep 4; 477(7365):477-81. Epub 2011 Sep 4.
- Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.[Sci Rep. 2015]Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.Zheng W, Qiu L, Wang R, Feng X, Han Y, Zhu Y, Chen D, Liu Y, Jin L, Li Y. Sci Rep. 2015 Jul 17; 5:12222. Epub 2015 Jul 17.
- A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice.[Mol Metab. 2021]A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice.Wu D, Eeda V, Undi RB, Mann S, Stout M, Lim HY, Wang W. Mol Metab. 2021 Dec; 54:101363. Epub 2021 Oct 25.
- Review Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.[Curr Top Med Chem. 2008]Review Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.Cho N, Momose Y. Curr Top Med Chem. 2008; 8(17):1483-507.
- Review PPARγ signaling and emerging opportunities for improved therapeutics.[Pharmacol Res. 2016]Review PPARγ signaling and emerging opportunities for improved therapeutics.Wang S, Dougherty EJ, Danner RL. Pharmacol Res. 2016 Sep; 111:76-85. Epub 2016 Jun 4.
- Figure 13, Differential Hydrogen-Deuterium Exchange (HDX) data for rosiglitazone...Figure 13, Differential Hydrogen-Deuterium Exchange (HDX) data for rosiglitazone, MRL24, probe ML244 and SR1848 - Probe Reports from the NIH Molecular Libraries Program
Your browsing activity is empty.
Activity recording is turned off.
See more...